Live Feeds
● TRACKER Updated 14d ago · 9 sources tracked

Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies

Eli Lilly is purchasing Massachusetts-based Merida Biosciences to expand its autoimmune drug pipeline. The deal is valued at approximately $2.88 billion, though some reports cite figures up to $2.9 billion or as low as $2.875 billion. Merida specializes in immunology and develops drugs targeting rogue antibodies. This acquisition marks a significant investment in the autoimmune sector and continues Lilly's growth strategy in the biotechnology space.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (9)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Eli Lilly is buying Merida Biosciences.
  • ✓ The acquisition targets autoimmune drugs designed to fight rogue antibodies.
  • ✓ Multiple sources value the deal at $2.88 billion.
  • ✓ Eli Lilly's headcount in Massachusetts has risen above 1,400.
🛡️ Source Corroboration: 9 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Eli Lilly announced the buyout of Merida Biosciences to target rogue antibodies in autoimmune patients.

Live updates

  1. Eli Lilly acquires Merida Biosciences for up to $2.88 billion

    Eli Lilly is purchasing Massachusetts-based Merida Biosciences to expand its autoimmune drug pipeline. The deal is valued at approximately $2.88 billion, though some reports cite figures up to $2.9 billion or as low as $2.875 billion. Merida specializes in immunology and develops drugs targeting rogue antibodies. This acquisition marks a significant investment in the autoimmune sector and continues Lilly's growth strategy in the biotechnology space.

    Why it matters

    The acquisition strengthens Lilly's portfolio of immune-related therapies. It also increases the company's presence in Massachusetts, where its local headcount has now exceeded 1,400 employees.

    What is confirmed

    • Eli Lilly is buying Merida Biosciences.
    • The acquisition targets autoimmune drugs designed to fight rogue antibodies.
    • Multiple sources value the deal at $2.88 billion.
    • Eli Lilly's headcount in Massachusetts has risen above 1,400.

    Still unconfirmed

    • The deal is valued at $2.875 billion.
    • The deal is valued at $2.9 billion.

    What to watch next

    • Regulatory approval of the merger
    • Clinical trial results for Merida's rogue antibody drugs
    Sources used for this update (10)
    1. Fierce Biotech — Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
    2. WSJ — Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion
    3. Bloomberg.com — Lilly to Buy Merida for $2.88 Billion in Autoimmune Push
    4. BioPharma Dive — Lilly adds to immune drug pipeline with $2.9B Merida buyout
    5. bizjournals.com — Lilly snags another Massachusetts biotech as local headcount surges past 1,400
    6. Barron's — Lilly (LLY): Pharma Giant Keeps Growing With $2.9 Billion Deal
    7. Yahoo Finance — Eli Lilly (LLY) Makes a $2.88 Billion Autoimmune Bet. What Could Go Right or Wrong?
    8. Yahoo Finance — SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
    9. CNBC — Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push
    10. finance.yahoo.com — Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community